

# About Blakes

---

## Who We Are

As one of Canada's top business law firms, Blake, Cassels & Graydon LLP (Blakes) provides exceptional legal services to leading businesses in Canada and around the world.

We focus on building long-term relationships with clients. We do this by providing unparalleled client service and the highest standard of legal advice, always informed by the business context.

Thanks to our clients, Blakes continues to earn top rankings and accolades. The Firm consistently stands out as a market leader in the *Chambers Canada Legal Guide*, which named us Corporate Law Firm of the Year based on our performance in the 2025 edition. We regularly earn top recognition across multiple litigation and dispute resolution categories, including nine consecutive years as Arbitration Firm of the Year at the Benchmark Canada Awards. In addition, our lawyers continue to be recognized as leaders in their fields in *The Canadian Legal Expert Directory*, Canada's leading guide to lawyers.

Blakes was named one of Canada's Top 100 Employers for 2025 and received its 15th Canada's Best Diversity Employers award that same year, underscoring our commitment to workplace excellence and inclusion.

Serving a diverse national and international client base, our integrated network of offices provides clients with access to the Firm's full spectrum of capabilities in virtually every area of business law. Whether an issue is local or multi-jurisdictional, practice-area specific or interdisciplinary, Blakes handles transactions of all sizes and levels of complexity.

Blakes also enthusiastically invests in the communities where we live and work — from pro bono work to supporting diversity, women's initiatives and the environment.

Since our founding in 1856, we've been on a constant quest to define best practices in professional services by delivering leading legal solutions to our clients worldwide.

## Professional Affiliations

Our international capabilities have been enhanced by our charter membership in Lex Mundi, the world's largest non-exclusive referral network of independent law firms in over 125 countries. This affiliation allows Blakes, whose clients conduct business worldwide, to arrange superior legal counsel virtually anywhere as needed. Blakes is also an advisory member of TechLaw Group, Inc., an international network of 28 law firms in 48 countries, whose primary mission is to advance clients' interests in all areas of technology-related business.

*Continued on reverse*

## Contacts

For more information, please contact:

### Bryson A. Stokes

Firm Managing Partner

+1-416-863-2179

[bryson.stokes@blakes.com](mailto:bryson.stokes@blakes.com)

### Geoffrey S. Belsher

Chair

+1-416-863-2223

[geoff.belsher@blakes.com](mailto:geoff.belsher@blakes.com)

### Birch Miller

Office Managing Partner, Calgary

+1-403-260-9613

[birch.miller@blakes.com](mailto:birch.miller@blakes.com)

### Jeffrey Merrick

Office Managing Partner, Vancouver

+1-604-631-3386

[jeff.merrick@blakes.com](mailto:jeff.merrick@blakes.com)

### Sébastien Vilder

Office Managing Partner, Montréal

+1-514-982-5080

[sebastien.vilder@blakes.com](mailto:sebastien.vilder@blakes.com)

### Kevin Rusli

Office Managing Partner, New York

+1-212-893-8014

[kevin.rusli@blakes.com](mailto:kevin.rusli@blakes.com)

### Jeff Lloyd

Office Managing Partner, London

+44-20-7429-3565 (London)

+1-416-863-5848 (Toronto)

[jeff.lloyd@blakes.com](mailto:jeff.lloyd@blakes.com)

# Expertise

## Practices

- Capital Markets
- Commercial Real Estate
- Competition & Antitrust
- Consumer Protection
- Corporate & Commercial
- Corporate Governance
- Cybersecurity
- Employment & Labour
- Energy & Energy Infrastructure
- Environmental
- Environmental, Social & Governance (ESG)
- Financial Services
- Financial Services Regulatory
- Foreign Investment
- Health & Product Regulatory
- Indigenous
- inSource
- Intellectual Property
- International Trade
- Investment Products & Asset Management
- Legal Translation
- Litigation & Dispute Resolution
- Major Projects
- Marketing & Advertising
- Mergers & Acquisitions
- Pensions, Benefits & Executive Compensation

- Political Law
- Privacy & Data Protection
- Procurement
- Regulatory
- Restructuring & Insolvency
- Shareholder Activism
- Tax
- Technology

## Sectors

- Automotive
- Aviation & Aerospace
- Banking
- Cannabis
- Communications
- Construction
- Defence
- Emerging Companies & Venture Capital
- FinTech
- Food, Beverage & Agribusiness
- Forestry
- Franchising
- Gaming
- Hospitality & Leisure
- Infrastructure
- Insurance
- Life Sciences
- Manufacturing
- Mining

- Oil & Gas
- Pension Funds
- Power
- Private Equity
- Public Sector Crisis & Compliance
- REITs
- Retail
- Sports
- Technology & Innovation

## 2025 Corporate Lawyers Who's Who: Vancouver

Blake, Cassels & Graydon LLP is the Grade AAA firm in this chart, followed by McCarthy Tétrault LLP; Fasken Martineau DuMoulin LLP; Lawson Lundell LLP; Borden Ladner Gervais LLP (BLG); Osler, Hoskin & Harcourt LLP; Cassels Brock & Blackwell LLP; and Bennett Jones LLP. In the next grade are Dentons Canada LLP; McMillan LLP; DLA Piper (Canada) LLP; Norton Rose Fulbright Canada LLP; DuMoulin Black LLP; and Stikeman Elliott LLP.



# Firm Successes

---



**Corporate Law Firm  
of the year**

— *Chambers Canada Awards 2024*



**Ranked Band 1  
in 33 Practice Areas**

— *Chambers Canada Legal Guide 2026*



**No. 1 Canadian Firm  
for Capital Markets**

— *Bloomberg, Financial Post and LSEG  
Rankings 2025*



**Arbitration Firm of the Year**

— *Benchmark Canada Awards 2025*



**Capital Markets  
Deal of the Year**

— *Canadian Law Awards 2025*



**Structured Finance &  
Securitization Deal of the Year**

— *IFLR Americas Awards 2025*

## Community Accomplishments

Blakes enthusiastically invests in the communities where we live and work by donating time and funds to charitable organizations, community agencies and volunteer boards. That includes more than 10,000 pro bono hours contributed each year.

In 2025, the Firm was named one of Canada's Top 100 Employers and received its 15th Canada's Best Diversity Employers award, underscoring our commitment to workplace excellence and inclusion. We have also been recognized with the United Way Centraide Canada's distinguished Thanks a Million award for 15 consecutive years for raising more than C\$1-million.

## Life Sciences

The Blakes Life Sciences group advises Canadian companies operating in the sector, along with international companies entering the Canadian market, expanding operations in Canada or conducting cross-border activities as part of international businesses. Our clients include established multinational, mid-market and emerging pharmaceutical, biotech, medical device, diagnostic product, and consumer product businesses as well as healthcare and health-related service providers, research institutions, financial institutions and investors.

We combine this sector specialization with regulatory, commercial, transactional/M&A, antitrust/competition, litigation, intellectual property, lobbying, tax, transfer pricing, privacy, cybersecurity and other expertise to meet the needs of our clients.

### Experience

#### Financing, M&A and Commercial

Life science companies looking to consolidate operations, acquire products or technology, divest themselves of non-strategic products or functions, or attract partners or funding for research, growth or ongoing operations, rely on Blakes for advice. In addition to our significant experience in public and private financing, investment and M&A transactions, we regularly advise clients in connection with product supply, distribution, licensing, technology transfer, collaborations, strategic alliances, joint ventures, and other industry-specific commercial arrangements.

#### Intellectual Property

Clients also retain Blakes for strategic advice on protecting their innovations and collaborating with others in the research and development of pharmaceutical, biological, medical device and combination products. We handle patent and other intellectual property (IP) protection, portfolio management, risk

management, and litigation. Our IP Litigation team has also handled numerous high-profile disputes for our life sciences clients, including the first patent infringement trial relating to a biosimilar product.

#### Health and Product Regulatory

We advise clients on all matters involving life sciences regulation, including product approvals and labelling, pricing and reimbursement, product listing agreements, rebates, interchangeability of drugs, conflicts of interest, procurement, anti-bribery, freedom of information, privacy and cybersecurity, product marketing and advertising, interaction with healthcare professionals, digital health, drug and device import and export, clinical trials, and product recalls.

#### Litigation and Dispute Resolution

When disputes arise, Blakes is a leading choice for representation across Canada. Our litigators are among the most experienced in class action and product liability defence. We have successfully represented clients in hundreds of class actions across the country, including the first medical device class action to go to trial in Canada, as well as other precedent-setting cases and multijurisdictional disputes requiring global coordination.

#### Public Sector Crisis and Compliance

When crisis strikes at the intersection of government and business, you need counsel who has a deep understanding of not only the law, but also reputational risk, government process, the press and political dynamics. Our role is to partner with the right government relations and communications organizations to help clients navigate the legal and governmental landscape. We conduct internal investigations to respond to government and regulator inquiries, and represent clients in government investigations.





## Joseph Garcia

Partner | Vancouver

+1-604-631-3307

[joseph.garcia@blakes.com](mailto:joseph.garcia@blakes.com)

Joseph's practice focuses on corporate finance and mergers and acquisitions. He advises public and private companies, investment dealers, venture capital and private equity funds and acts as independent counsel to boards of directors. Joseph has extensive experience advising on all types of merger and acquisition and corporate finance transactions including public and private equity and debt financings, take-over and issuer bids, share and asset acquisitions and divestitures, and regulatory and stock exchange compliance work.

Prior to his career in law, Joseph worked in corporate finance with a national investment bank and in clinical research with a multinational pharmaceutical company.

*Joseph provides legal services through Joseph Garcia Law Corporation.*

## Select Experience

Recent representative transactions include advising:

- Eupraxia in connection with its US\$80.5-million public offering of common shares
- ESSA in connection with its acquisition by XenoTherapeutics
- Weyerhaeuser in connection with the sale of its Princeton, British Columbia lumber mill to the Gorman Group
- Access Planning in connection with its acquisition by Nelson/Nygaard
- DCx Biotherapeutics in its licensing and acquisition of certain assets from Repare Therapeutics
- Eupraxia in connection with its C\$44.5-million non-brokered private placement of preferred shares
- enGene in connection with its US\$60-million private placement of common shares
- Alpha-9 Oncology in connection with its US\$175-million series C preferred share financing
- Orpyx Medical in connection with its US\$20-million financing by Perceptive Advisors
- Mediphage in connection with its seed round financing
- Eupraxia in connection with its MJDS direct listing on the NASDAQ Capital Market
- NervGen in connection with its C\$23-million public offering of units
- Eupraxia in connection with its C\$33.9-million public offering of common shares
- enGene in connection with its US\$200-million private placement of common shares
- Xenon Pharmaceuticals in connection with its US\$345-million public offering of common shares

- enGene in connection with its US\$138-million de-SPAC merger with Forbion European Acquisition
- Eupraxia Pharmaceuticals in connection with its C\$22.3-million private placement of common shares
- Abdera in connection with its US\$110-million Series B preferred share financing
- Neovasc in connection with its acquisition by Shockwave for approximately US\$100-million
- Alpha-9 Theranostics in connection with its US\$75-million Series B preferred share financing
- Zymeworks in connection with its plan of arrangement transaction to become a Delaware corporation
- The underwriters in connection with the US\$20-million public offering of units by Medicenna Therapeutics
- NervGen Pharma in connection with its US\$15.23-million private placement of units
- Xenon Pharmaceuticals in connection with its US\$287.5-million public offering of common shares
- Incisive Genetics in connection with its C\$12-million seed financing
- Eupraxia Pharmaceuticals in connection with its C\$14.7-million overnight marketed public offering of units
- Zymeworks in connection with its US\$115-million public offering of common shares
- Trillium Therapeutics in connection with its acquisition by Pfizer for US\$2.22-billion
- Oquest Business Solutions in connection with its acquisition by Deloitte
- Xenon Pharma in connection with its US\$345-million public offering of common shares
- Boreal Genomics in connection with its acquisition by Natera
- iCo Therapeutics in connection with its reverse take-over transaction by Satellos Bioscience
- Complex Biotech Discovery Ventures in connection with its acquisition by Delic Labs
- Terry Fox Research Institute in connection with the establishment of the Digital Health and Discovery Platform
- Alpha-9 Theranostics in connection with its US\$11-million Series A preferred share financing
- NewGen Therapeutics in connection with its TSXV qualifying transaction with Rakovina Therapeutics
- Vivifi Biotech, an affiliate of Parkinson's UK, in connection with its acquisition of certain assets of MedGenesis Therapeutics
- Tevosol in connection with its acquisition by Bridge to Life
- Essa Pharma in connection with its US\$150-million public offering of common shares
- Eupraxia in connection with its C\$41-million initial public offering of common shares and warrants on the Toronto Stock Exchange
- Xenon Pharmaceuticals in connection with its US\$115-million public offering of common shares
- Neovasc in connection with its US\$72-million MJDS registered direct offering of common shares
- Notch Therapeutics in connection with its US\$85-million Series A financing
- adMare BioInnovations in connection with the C\$20-million launch of FORUS Therapeutics
- adMare BioInnovations in connection with the C\$8-million seed financing of Abdera Therapeutics
- A syndicate of agents in connection with the C\$24.2-million private placement of subscription receipts issued by Sustainable Produce Urban Delivery

- AbCellera Biologics in connection with its US\$555.5-million initial public offering of common shares on NASDAQ
- The underwriters in connection with the up to US\$25-million at-the-market offerings of common shares by Medicenna Therapeutics
- Novoheart in connection with its going private transaction
- Neovasc in connection with its US\$6.1-million MJDS registered direct offering of common shares
- NervGen in connection with its C\$6.45-million public offering of units
- Neovasc in connection with its US\$12.6-million MJDS registered direct offering of common shares
- ESSA Pharma in connection with its US\$49-million public offering of common shares
- Neoleukin Therapeutics in connection with the sale of its subsidiary, Aquinox Pharma, to Taro Pharmaceutical
- Neovasc in connection with its US\$11.5-million MJDS registered direct offering of units
- Correvio Pharma in connection with its acquisition by ADVANZ Pharma for US\$76-million
- Essa Pharma in connection with its up to US\$35-million at-the-market common share offering
- Xenon Pharmaceuticals in connection with its US\$69-million public offering of common shares
- Zymeworks in connection with its US\$320.8-million public offering of common shares and pre-funded warrants
- adMare BioInnovations in connection with its business combination with Accel-Rx
- Neovasc in connection with its US\$10-million MJDS registered direct offering of units
- Zymeworks in connection with its US\$75-million at-the-market common share offering
- Xenon Pharmaceuticals in connection with its US\$50-million at-the-market common share offering
- ESSA in connection with its US\$36-million public offering of common shares and pre-funded warrants
- Zymeworks in connection with its US\$201.3-million cross border prospectus offering of common shares
- Centre for Drug Research and Development in connection with its business combination with NEOMED Institute to create adMare BioInnovations
- Novoheart in connection with its acquisition of Xellera Therapeutics
- ESSA Pharma in connection with its acquisition of Realm Therapeutics
- The underwriters in connection with the US\$350-million private placement of 5.25% convertible senior notes due 2024 by Aphria
- Jones Brown in connection with its sale to Arthur J. Gallagher & Co.
- Helius Medical in connection with its US\$20.1-million MJDS prospectus offering of common shares
- Jam City in connection with the acquisition of Bingo Pop from Uken Games
- Xenon Pharmaceuticals in connection with its US\$63-million prospectus offering of common shares
- Zymeworks in connection with its US\$97.8-million MJDS prospectus offering of common shares
- Anandia Laboratories in connection with its acquisition by Aurora Cannabis for C\$115-million in common shares



- Cardiome Pharma in connection with the acquisition of its Canadian business portfolio by Cipher Pharmaceuticals for C\$25.5-million pursuant to a statutory plan of arrangement
- Helius Medical in connection with its US\$14.1-million prospectus offering of common shares and warrants and its concurrent listing on the NASDAQ Global Select Market
- Seaspan in connection with its US\$500-million private placements of 5.50% debentures and warrants to Fairfax Financial Holdings
- ESSA in connection with its US\$26-million prospectus offering and concurrent private placement of common shares and pre-funded warrants
- Neovasc in connection with its US\$37.5-million underwritten offering of Series A and Series B units (comprised of a combination of common shares or Series D pre-funded warrants, Series C units and Series A, B, C and F warrants to purchase common shares) and concurrent US\$27.8-million private placement of notes and Series E warrants to purchase common shares
- The underwriters in connection with the C\$11.5-million prospectus offering of units by Oncolytics Biotech
- Zymeworks in connection with its US\$64-million initial public offering of common shares and listing on the Toronto Stock Exchange and the New York Stock Exchange
- Helius Medical in connection with its C\$12.5-million MJDS prospectus offering of common shares
- Trilogy International in connection with its US\$875-million business combination with Alignvest Acquisition Corporation, a special purpose acquisition corporation (SPAC)
- Volkswagen Financial Services AG in connection with its acquisition of PayByPhone
- Neovasc in connection with the sale of its tissue business and concurrent private placement to Boston Scientific for US\$75-million
- Weyerhaeuser in connection with the sale of its Cellulose Fibers pulp mill in Alberta to International Paper
- Response Biomedical in connection with its going-private transaction
- ESSA in connection with its US\$10-million term loan from Silicon Valley Bank
- The underwriters in connection with the US\$25.9-million prospectus offering of common shares by Xenon Pharmaceuticals and the concurrent US\$8.6-million secondary offering
- 3D Signatures in connection with the closing of its qualifying transaction on the TSX Venture Exchange and concurrent C\$5.45-million private placement of common shares
- The underwriters in connection with the exchange offer of DFC Finance's US\$800-million outstanding principal amount of 10.5% senior secured notes due in 2020
- Opko Health in connection with its acquisition of Transition Therapeutics for US\$60-million in common shares
- Cardiome Pharma in connection with its US\$34.5-million MJDS prospectus offering of common shares
- SciVac in connection with its acquisition of VBI Vaccines for US\$92.1-million in shares
- Helius Medical in connection with its C\$10.2-million prospectus offering and its listing on the Toronto Stock Exchange
- Private company in connection with its US\$25-million Series C preferred share financing
- ESSA Pharma in connection with its US\$15-million private placement of units
- Zymeworks in connection with its US\$61.5-million mezzanine preferred share financing

- Zymeworks in connection with its equity investment and optional merger agreement with Kairos Therapeutics
- Cardiome Pharma in connection with its up to US\$20-million prospectus offering
- CPI Card Group in connection with its US\$150-million initial public offering of common shares, concurrent US\$22.5-million secondary offering, and listing on the Toronto Stock Exchange and NASDAQ Global Select Market
- Cardiome Pharma in connection with its US\$23-million prospectus offering of common shares
- VRG Capital in connection with its backing of a management buy-out of Jones Brown, and the subsequent acquisition of Pearson Dunn Insurance
- UrtheCast in connection with the C\$100-million acquisition of the Earth Observation business of Elecnor and its concurrent prospectus offering of C\$100-million of subscription receipts
- SciVac in connection with its reverse take-over transaction of Levon Resources with an aggregate transaction value of C\$356-million and its listing on the Toronto Stock Exchange
- The underwriters in connection with the US\$55.2-million prospectus offering of common shares by Trillium Therapeutics
- Urthecast in connection with its C\$17.25-million prospectus offering of common shares
- Neovasc in connection with its US\$74.9-million MJDS prospectus offering of common shares and the concurrent US\$11.9-million secondary prospectus offering
- Zymeworks in connection with its C\$27-million private placement and the expansion of its strategic collaboration with Eli Lilly and Company
- The underwriters in connection with the US\$41.4-million initial public offering of common shares by Xenon Pharmaceuticals and its listing on the NASDAQ Global Select Market
- Neovasc in connection with its C\$25-million prospectus offering of common shares
- The underwriters in connection with the US\$60-million prospectus offering of common shares by Tekmira Pharmaceuticals
- The underwriters in connection with the US\$53-million initial public offering of common shares by Aquinox Pharmaceuticals and its listing on the NASDAQ Global Select Market
- Cardiome Pharma in connection with its C\$15-million prospectus offering of common shares and the concurrent C\$15-million secondary prospectus offering
- Cardiome Pharma in connection with its C\$30-million at-the-market prospectus offering of common shares
- The agent in connection with the US\$52-million private placement of units of Aurinia Pharmaceuticals
- Aequus Pharmaceuticals in connection with its private placement, prospectus filing and direct listing on the TSX Venture Exchange
- ESSA Pharma in connection with its private placement, prospectus filing and direct listing on the TSX Venture Exchange
- iCo Therapeutics in connection with its C\$6.75-million prospectus offering of common shares
- UrtheCast in connection with its C\$10-million prospectus offering of common shares
- Cardiome Pharma in connection with its cross-border acquisition of Correvio
- Response Biomedical in connection with its private placement of subscription receipts

- GenomeDx Biosciences in connection with its Series B preferred share financing
- Boreal Genomics in connection with its Series C preferred share financing
- UrtheCast in connection with its reverse takeover transaction of Longford Energy, concurrent financing and listing on the Toronto Stock Exchange
- enGene in connection with its Series A preferred share financing
- Aspreva Pharmaceuticals in connection with its acquisition by Galenica for US\$950-million
- ID Biomedical in connection with its acquisition by GlaxoSmithKline for C\$1.7-billion

## Awards & Recognition

Joseph has received the following awards:

- Milton Wong Community Leadership Award – Life Sciences BC Awards 2024
- Canadian Financial & Transactional Attorney of the Year – LMG Life Sciences Awards 2018
- Visionary Leadership – BIOTEC Canada Gold Leaf Awards 2015
- Partner/Advisor of the Year – Life Sciences BC Awards 2015
- Canadian Financial & Transactional Attorney of the Year – LMG Life Sciences Awards 2015

Joseph is also featured as a leading lawyer in numerous publications including:

- *Lexpert Special Edition: Health Sciences 2025*
- *Lexpert Special Edition: Technology 2025*
- *Lexpert Special Edition: Finance and M&A 2025*
- *The Canadian Legal Lexpert Directory 2025* (Life Sciences & Health, Corporate Finance & Securities, Corporate Commercial Law, Technology Transactions, Mergers & Acquisitions, Corporate Mid-Market)
- *Chambers Canada Legal Guide 2025* (Life Sciences: Corporate/Commercial)
- *The Best Lawyers in Canada 2025* (Biotechnology and Life Sciences Practice, Corporate Governance Practice, Corporate Law, Health Care Law, Mergers and Acquisitions Law, Securities Law)
- *Lexology Index: Canada – 2023–2024* (Life Sciences)
- *Lexology Index: Life Sciences 2024* (Life Sciences – Transactional)
- *IFLR1000: The Guide to the World's Leading Financial Law Firms 2024* (Capital Markets: Equity, M&A)
- Best Lawyers: "Lawyer of the Year" 2022 (Biotechnology, Vancouver)
- *LMG Life Sciences: The Definitive Guide to the Leading Life Sciences Firms and Attorneys in North America 2022* (Star Attorney in Canada)
- *The 2017 Lexpert Guide to the Leading US/Canada Cross-Border Corporate Lawyers in Canada* (Corporate Finance and Securities)

## Professional Activities

Joseph has lectured extensively on corporate governance and advanced securities law topics. He has chaired The Continuing Legal Education Society of British Columbia Corporate Governance courses in 2011, 2013, 2015, 2017, 2020 and 2022, and participated in the advanced securities law courses from 2007–2009, 2011 and from 2013–2015.

Joseph is a director of Science World and director emeritus of LifeSciences BC. He is a former director of the Canadian Glycomics Network and Genome BC. He is a member of the BIOTECanada Legal Affairs Advisory Board and the Canadian Bar Association.

## **Education**

Admitted to the British Columbia Bar – 1997

LLB, University of British Columbia – 1996

BA (Economics (Health Care)), McMaster University – 1993

BSc (Hon., Pharmacology and Human Biology), University of Toronto – 1990



## Kyle Misewich

Partner | Vancouver

+1-604-631-3398

kyle.misewich@blakes.com

Kyle practises corporate and securities law, including public and private company financings, mergers and acquisitions, and corporate reorganizations. He also advises clients in connection with securities law compliance, disclosure obligations, stock exchange matters, corporate governance and general corporate law. Kyle represents clients in a broad range of industries including life sciences, technology and mining.

### Select Experience

Recent representative transactions include assisting:

#### M&A and Reorganizations

- enGene in connection with its US\$138-million de-SPAC merger with Forbion European Acquisition
- Neovasc in connection with its acquisition by Shockwave for approximately US\$100-million
- NioCorp Developments Ltd. on its business combination with GX Acquisition Corp. II, a US special purpose acquisition corporation (SPAC), and concurrent financings valued at up to US\$71.9-million
- Trilogy International Partners in connection with the sale of its subsidiary, Two Degrees, for NZ\$1.315-billion
- Trillium Therapeutics Inc. in connection with its acquisition by Pfizer for US\$2.22-billion
- Absolute Software Corporation in connection with its US\$340-million acquisition of NetMotion Software, Inc.
- CRH Medical Corporation in connection with its acquisition by Well Health Technologies Corp. in a deal valued at US\$372.9-million
- Novoheart Holdings Inc. in a going private transaction valued at approximately C\$100-million
- Atico Mining Corporation in connection with its acquisition of Toachi Mining Inc.
- Washington Companies in connection with its C\$1.5-billion acquisition of Dominion Diamond Corporation
- Trilogy International Partners on a US\$875-million business combination with Alignvest Acquisition Corporation, a special purpose acquisition corporation (SPAC)
- Neovasc in connection with the sale of its tissue business and concurrent private placement to Boston Scientific for US\$75-million
- Reservoir Minerals Inc. on its private placement, credit agreement and plan of arrangement with Nevsun Resources Ltd. for a total of US\$575-million

- Capstone Mining in connection with its acquisition of the Pinto Valley Mine from BHP Billiton for US\$650-million
- Lithium One Inc. in connection with its acquisition by Galaxy Resources for C\$112-million in exchangeable shares

## **Corporate Finance**

- enGene in connection with its US\$60-million private placement of common shares
- Svante Technologies Inc. in connection with convertible note financings of US\$50-million by Canada Growth Fund and C\$15-million by InBC Investment Corp.
- Alpha-9 Oncology in connection with its US\$175-million Series C preferred share financing
- Orpyx Medical in connection with its US\$20-million financing by Perceptive Advisors
- NervGen Pharma in connection with its C\$23-million public offering of units
- enGene in connection with its US\$200-million private placement of common shares
- The underwriters in separate public offerings of CubicFarm Systems Corp. for gross proceeds of C\$20-million, C\$25.3-million, C\$16.2-million and C\$2.8-million
- The underwriters in connection with a US\$20-million public offering of units by Medicenna Therapeutics
- NervGen Pharma in connection with its US\$15.23-million private placement of units
- ESSA Pharma Inc. in connection with its US\$130-million underwritten public offering of common shares
- Kadestone Capital Corp. on its formation and initial public offering
- The underwriters in a C\$23-million bought deal public offering of units of Rubicon Organics Inc.
- Neovasc in connection with its US\$72-million MJDS registered direct offering of common shares
- Svante Technologies Inc. in connection with its US\$16-million Series C preferred share financing, US\$100-million Series D preferred share financing and US\$318-million Series E preferred share financing
- ESSA Pharma in connection with its US\$26-million prospectus offering and concurrent private placement of common shares and pre-funded warrants
- Neovasc in connection with its US\$37.5-million underwritten offering of Series A and Series B units (comprised of a combination of common shares or Series D pre-funded warrants, Series C units and Series A, B, C and F warrants to purchase common shares) and concurrent US\$27.8-million private placement of notes and Series E warrants to purchase common shares
- The underwriters of B2Gold Corp. on its at-the-market offering of up to US\$100-million
- The underwriters on a private placement of flow-through common shares of Sabina Gold & Silver Corp. for gross proceeds of approximately C\$34.5-million
- Esperanza Resources Corp. on a private placement of special warrants for gross proceeds of approximately C\$34-million
- NovaGold Resources Inc. on a public offering of common shares for gross proceeds of approximately US\$332.5-million

## **Awards & Recognition**

Kyle is recognized as a leading lawyer in the following publications:



- *The Best Lawyers in Canada 2026* (Mergers and Acquisitions Law; Securities Law)
- *Lexpert Special Edition: Finance and M&A 2024*
- *The Canadian Legal Lexpert Directory 2024* (Leading Lawyers to Watch – Corporate Finance & Securities)

## **Professional Activities**

Kyle is co-chair of The Continuing Legal Education Society of British Columbia Corporate Governance course.

Kyle is a member of The Law Society of British Columbia and the Canadian Bar Association.

## **Education**

Admitted to the British Columbia Bar – 2011

JD, University of Victoria – 2010

BBA (Hon.), Simon Fraser University – 2007



## Emma Costante

Partner | Vancouver

+1-604-631-3332

[emma.costante@blakes.com](mailto:emma.costante@blakes.com)

Emma is a corporate lawyer advising domestic and international clients on a range of business matters, including financings, mergers and acquisitions, go-public events, complex shareholder negotiations, corporate governance, commercial transactions, joint ventures and partnerships.

Emma's practice covers a broad range of sectors and industries, including life sciences, health care, SaaS, AI and quantum computing, clean tech, and natural resources. A large part of Emma's practice focuses on supporting innovative growth companies and particularly in the life science industry. She helps create negotiated solutions among stakeholders, including founder exits, government contracts and complex shareholder agreements.

## Select Experience

### Mergers, Acquisitions and Financings

- Access Planning in connection with its acquisition by Nelson\Nygaard
- DCx Biotherapeutics in its licensing and acquisition of certain assets from Repare Therapeutics
- Convergent in connection with its purchase of the security division of Delco Automation Inc. for C\$55-million
- Eupraxia in connection with its C\$44.5-million non-brokered private placement of preferred shares
- Alpha-9 Oncology in connection with its US\$175-million Series C preferred share financing
- Orpyx Medical in connection with its US\$20-million financing by Perceptive Advisors
- Mediphage in connection with its seed round financing
- Convergent in connection with its acquisition of Panavidéo
- Disruption Ventures in connection with the C\$1.5-million seed financing of Ginger Desk
- HTEC in connection with its raise of C\$337-million from the Canada Infrastructure Bank
- Mediphage Bioceuticals in connection with its seed round financing
- Conuma in connection with its purchase of the Quintette coal mine assets from Teck Resources for C\$120-million
- enGene in connection with its public transaction through a merger with a SPAC, Forbion European Acquisition Corporation, in a deal with US\$138-million in gross proceeds
- Abdera in connection with its US\$110-million Series B financing

- Tasktop Technologies Incorporated on its C\$100-million in new financing from Sumeru Equity Partners
- Alpha-9 Theranostics in connection with its US\$75-million Series B financing
- Incisive Genetics in connection with its C\$12-million seed financing
- Notch Therapeutics in connection with its US\$85-million Series A financing
- Later.com on its acquisition by Mavrck, in a deal funded by Summit Partners
- adMare BioInnovations in connection with the C\$8-million seed financing of Abdera Therapeutics
- Hutton Family Holdings Ltd. in its acquisition of the assets of Fairview Cellars Winery
- Alpha-9 Theranostics in connection with its US\$11-million Series A financing
- AbCellera Biologics in connection with its US\$555.5-million initial public offering of common shares on NASDAQ
- Brewster Travel Canada Inc. (an affiliate of Viad Corp.) on its acquisition of a majority equity interest in Mountain Park Lodges
- D-Wave Systems Inc. in its public transaction through a merger with a SPAC, DPCM Capital, Inc., in a deal with an implied value of US\$1.2-billion
- Beijing BDStar Navigation Co., Ltd. on its acquisition of Canadian mobile positioning technology company Rx Networks Inc. with a total deal value of approximately C\$31-million
- Trilogy International Partners on its US\$875-million business combination with Allinvest Acquisition Corporation, a special purpose acquisition corporation (SPAC)
- Cognizant on their acquisition of Idea Couture, a privately held firm that offers digital innovation, strategy, design and technology services
- Dominion Lending Centres Group in the sale of a 60% interest to Founders Advantage Capital Corp. for C\$78-million
- Foley's Candies in its sale to Yellow Point Equity Partners
- Concert Infrastructure, Bird Construction and Bird Capital in their successful bid to construct, finance and maintain nine public-private partnership schools in Saskatchewan

### **Corporate Governance and Complex Commercial Transactions**

- Centre for Drug Research and Development in connection with its business combination with NEOMED Institute to create adMare BioInnovations
- Acting for joint venture partners in forming various forms of joint ventures in the natural resource and manufacturing sectors
- Representing companies and shareholders in complex governance matters, including the negotiation and renegotiation of complex multi-party shareholder agreements
- Negotiating and drafting all manner of commercial and operational contracts specific to the retail, technology, agricultural and natural resource sectors

### **Competition and Foreign Investment**

- GlaxoSmithKline in connection with the Canadian antitrust aspects of its consumer healthcare, vaccines and oncology transactions with Novartis AG

- Marine Harvest ASA on its acquisition of a significant minority interest in Grieg Seafood ASA

## Awards & Recognition

Emma is recognized by the following publications:

- *The Best Lawyers in Canada* – 2025–2026 (Corporate Law)
- *Thomson Reuters Stand-out Lawyers 2024 – Independently Rated Lawyers* (As nominated by senior in-house counsel)
- *Best Lawyers: Ones to Watch in Canada* – 2022–2023 (Corporate Law)

## Publications

- *Co-author : British Columbia Business Corporations Act & Commentary*  
LexisNexis Canada, 2024 Edition, 2024.
- *Co-author : British Columbia Business Corporations Act & Commentary*  
LexisNexis Canada, 2023 Edition, 2023.

## Education

Admitted to the British Columbia Bar – 2015

Admitted to the Ontario Bar – 2013

JD, University of Toronto – 2012

BA (Recipient of the Brian Coghlan Memorial Prize in Economics), McGill University – 2009